Recent clinical developments in thrombolysis in acute myocardial infarction
Related Experiment Videos
1University of Utah Medical School, Salt Lake City.
Insights
Early reperfusion therapy for acute myocardial infarction (AMI) significantly improves outcomes. Prompt treatment, ideally within 2-3 hours of symptom onset, is crucial for myocardial salvage and reduced mortality.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute myocardial infarction (AMI) treatment aims for rapid reperfusion to salvage heart muscle.
- Streptokinase achieves reperfusion in a significant percentage of AMI patients, but timing is critical.
Purpose of the Study:
- To review the efficacy and limitations of current reperfusion therapies for AMI.
- To highlight the importance of early intervention for improved patient outcomes.
- To discuss emerging thrombolytic agents and adjunctive therapies.
Main Methods:
- Review of existing studies on thrombolytic therapy for acute myocardial infarction.
- Analysis of reperfusion rates, timing of intervention, and patient outcomes.
- Discussion of bleeding risks, reocclusion rates, and mortality associated with thrombolysis.
Main Results:
- Intracoronary streptokinase yields 70-75% reperfusion; intravenous yields ~50%.
- Treatment initiated after 4 hours shows no significant ventricular function improvement.
- Early intervention (within 2-3 hours) consistently demonstrates benefit and reduces early mortality.
- Bleeding risk is ~5%, with rare mortality (<0.5%); reocclusion rates are 15-20%.
Conclusions:
- Early reperfusion therapy is a major advance in managing AMI.
- Timely intervention is paramount for myocardial salvage and improved survival.
- Development of safer, more effective thrombolytics (e.g., t-PA, APSAC) and adjunctive angioplasty are promising.
Abstract:
Intracoronary streptokinase can accomplish reperfusion in 70 to 75% of patients with acute myocardial infarction (AMI), and intravenous streptokinase in approximately 50% of those with prior documented coronary occlusion. The time constraints for accomplishing significant myocardial salvage have proved to be quite restrictive, however. Studies in which treatment has begun after an average of 4 hours of symptoms have not shown significant improvement in ventricular function. In contrast, those in which intervention has been applied earlier, particularly in less than 2 to 3 hours, have consistently shown benefit. The price for applying thrombolytic therapy includes the risk of severe bleeding (about 5%) but, fortunately, mortality as a result of bleeding has been rare (less than or equal to 0.5%). Reperfusion may be only transient or incomplete (and insufficient). An early reocclusion rate of about 15 to 20% has been commonly noted, in fact. Recently, major studies have pointed to a reduction in early mortality in patients treated early (within about 3 hours) after the onset of symptoms. Much interest is now being focused on developing safer, more effective thrombolytic agents such as tissue plasminogen activator and anisoylated plasminogen streptokinase activator complex (APSAC). Adjunctive therapy with coronary angioplasty is also being applied. In the judgement of many, reperfusion therapy may represent the greatest advance in the approach to AMI of the current decade.